{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:39:25Z","timestamp":1707525565297},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,26]]},"DOI":"10.7759\/cureus.51108","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T12:37:43Z","timestamp":1703594263000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Primary Central Nervous System Lymphoma That Developed in a Patient Receiving Fingolimod Therapy for Multiple Sclerosis"],"prefix":"10.7759","author":[{"given":"Kengo","family":"Takanashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinjiro","family":"Fukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Matsubayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1653-y","article-title":"An updated histological classification system for multiple sclerosis lesions","volume":"133","author":"Kuhlmann T","year":"2017","unstructured":"Kuhlmann T, Ludwin S, Prat A, Antel J, Br\u00fcck W, Lassmann H. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 2017, 133:13-24. 10.1007\/s00401-016-1653-y","journal-title":"Acta Neuropathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-021-00139-8","article-title":"Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders","volume":"3","author":"Bayas A","year":"2021","unstructured":"Bayas A, Berthele A, Hemmer B, Warnke C, Wildemann B. Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders. Neurol Res Pract. 2021, 3:45. 10.1186\/s42466-021-00139-8","journal-title":"Neurol Res Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos L","year":"2010","unstructured":"Kappos L, Radue EW, O'Connor P, et al.. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010, 362:387-401. 10.1056\/NEJMoa0909494","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen JA","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, et al.. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010, 362:402-15. 10.1056\/NEJMoa0907839","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331499","article-title":"Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial","volume":"94","author":"Diouf I","year":"2023","unstructured":"Diouf I, Malpas CB, Sharmin S, et al.. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. J Neurol Neurosurg Psychiatry. 2023, 94:1004-11. 10.1136\/jnnp-2023-331499","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00451.x","article-title":"FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system","volume":"158","author":"Brinkmann V","year":"2009","unstructured":"Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009, 158:1173-82. 10.1111\/j.1476-5381.2009.00451.x","journal-title":"Br J Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005561","article-title":"Preapproval and postapproval evidence on drugs for multiple sclerosis","volume":"90","author":"Gerardi C","year":"2018","unstructured":"Gerardi C, Bertele' V, Rossi S, Garattini S, Banzi R. Preapproval and postapproval evidence on drugs for multiple sclerosis. Neurology. 2018, 90:964-73. 10.1212\/WNL.0000000000005561","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-21","article-title":"Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension","volume":"14","author":"Kira J","year":"2014","unstructured":"Kira J, Itoyama Y, Kikuchi S, et al.. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurol. 2014, 14:21. 10.1186\/1471-2377-14-21","journal-title":"BMC Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06367-3","article-title":"Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod","volume":"44","author":"Morillos MB","year":"2023","unstructured":"Morillos MB, de Aguiar PH, Franceschini PR, Duarte J\u00c1, Piccini CD, Finkelsztejn A. Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod. Neurol Sci. 2023, 44:361-3. 10.1007\/s10072-022-06367-3","journal-title":"Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000774","article-title":"Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis","volume":"33","author":"Christopher KL","year":"2017","unstructured":"Christopher KL, Elner VM, Demirci H. Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis. Ophthalmic Plast Reconstr Surg. 2017, 33:e73-5. 10.1097\/IOP.0000000000000774","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.11.012","article-title":"Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving fingolimod","volume":"19","author":"Manouchehri N","year":"2018","unstructured":"Manouchehri N, Mirmosayyeb O, Badihian S, Shaygannejad V. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving fingolimod. Mult Scler Relat Disord. 2018, 19:121-3. 10.1016\/j.msard.2017.11.012","journal-title":"Mult Scler Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.7280","article-title":"Fingolimod-induced bladder lymphoma in a patient with multiple sclerosis","volume":"11","author":"Vaheb S","year":"2023","unstructured":"Vaheb S, Ghaffary EM, Shaygannejad V, Mirmosayyeb O. Fingolimod-induced bladder lymphoma in a patient with multiple sclerosis. Clin Case Rep. 2023, 11:e7280. 10.1002\/ccr3.7280","journal-title":"Clin Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102776","article-title":"Primary mediastinal large B-cell lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis","volume":"49","author":"Chacko JA","year":"2021","unstructured":"Chacko JA, Strati P, Stout PW, Archer RL, Baltz BP, Chacko JG. Primary mediastinal large B-cell lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021, 49:102776. 10.1016\/j.msard.2021.102776","journal-title":"Mult Scler Relat Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.357","article-title":"Age, gender, and racial differences in incidence and survival in primary CNS lymphoma","volume":"105","author":"Villano JL","year":"2011","unstructured":"Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011, 105:1414-8. 10.1038\/bjc.2011.357","journal-title":"Br J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577721","article-title":"Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis","volume":"360","author":"Sriwastava S","year":"2021","unstructured":"Sriwastava S, Kataria S, Srivastava S, et al.. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2021, 360:577721. 10.1016\/j.jneuroim.2021.577721","journal-title":"J Neuroimmunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316886","article-title":"Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS","volume":"89","author":"Wattjes MP","year":"2018","unstructured":"Wattjes MP, Wijburg MT, van Eijk J, et al.. Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS. J Neurol Neurosurg Psychiatry. 2018, 89:535-41. 10.1136\/jnnp-2017-316886","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/201929-a-case-of-primary-central-nervous-system-lymphoma-that-developed-in-a-patient-receiving-fingolimod-therapy-for-multiple-sclerosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:27Z","timestamp":1707509487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/201929-a-case-of-primary-central-nervous-system-lymphoma-that-developed-in-a-patient-receiving-fingolimod-therapy-for-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.51108","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,26]]}}}